Nuclidium AGBasel-based Nuclidium AG has secured an additional tranche for its ongoing Series B financing round, bringing the total to approximately €115 million. The theranostics company is developing copper-based radiopharmaceuticals that are used both for diagnostic imaging and therapeutic applications.
ADVERTISEMENT